Brolucizumab effectiveness in pigment epithelium detachment due to exudative AMD in naïve treatment or non-responder patients.

IF 1.4 4区医学 Q3 OPHTHALMOLOGY

European Journal of Ophthalmology Pub Date : 2024-11-01 Epub Date: 2024-03-11 DOI:10.1177/11206721241238391

Claudio Furino, Valeria Albano, Maria D'Addario, Michele Reibaldi, Francesco Boscia, Giovanni Alessio

{"title":"Brolucizumab effectiveness in pigment epithelium detachment due to exudative AMD in naïve treatment or non-responder patients.","authors":"Claudio Furino, Valeria Albano, Maria D'Addario, Michele Reibaldi, Francesco Boscia, Giovanni Alessio","doi":"10.1177/11206721241238391","DOIUrl":null,"url":null,"abstract":"Purpose: To investigate outcomes after Brolucizumab injection in naïve treatment or non-responder patients with exudative age-related macular degeneration (AMD).Methods: It is a retrospective, comparative, cohort study conducted at the tertiary referral center of the University Hospital Polyclinic of Bari, for 5 years, from November 2017 until May 2022. 41 eyes with wet-AMD (w-AMD) were included, undergoing anti-vascular endothelial growth factor (VEGF) intravitreal injections. The sample was divided into two groups, the Bro-Switch group, and the Bro-Naïve group. The Bro-Switch group previously received a slot of other anti-VEGF intravitreal drugs. The Bro-Naïve group received Brolucizumab (Bro) as the first treatment. The pigment epithelium detachment (PED) and the best-corrected visual acuity (BCVA) outcomes before and after Bro-injection were evaluated.Results: A significant reduction in PED measurement was registered in all eyes treated with Bro-injection (p = 0.35). The Bro-Naïve group improved better in PED measurement (mean difference: 297.92 ± 72,32) as compared to the Bro-Switch group (mean difference: 185.06 ± 11.07). On the contrary, no significant reduction in BCVA in the two groups was recorded (p = 0.66).Conclusion: We suggest Bro-injection for w-AMD as effective anatomical outcomes in PED flattening, but not similar in visual results. Although this study evaluated short-term outcomes, the hopeful results can lead to interesting medium-long time effects.","PeriodicalId":12000,"journal":{"name":"European Journal of Ophthalmology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/11206721241238391","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/11 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To investigate outcomes after Brolucizumab injection in naïve treatment or non-responder patients with exudative age-related macular degeneration (AMD).

Methods: It is a retrospective, comparative, cohort study conducted at the tertiary referral center of the University Hospital Polyclinic of Bari, for 5 years, from November 2017 until May 2022. 41 eyes with wet-AMD (w-AMD) were included, undergoing anti-vascular endothelial growth factor (VEGF) intravitreal injections. The sample was divided into two groups, the Bro-Switch group, and the Bro-Naïve group. The Bro-Switch group previously received a slot of other anti-VEGF intravitreal drugs. The Bro-Naïve group received Brolucizumab (Bro) as the first treatment. The pigment epithelium detachment (PED) and the best-corrected visual acuity (BCVA) outcomes before and after Bro-injection were evaluated.

Results: A significant reduction in PED measurement was registered in all eyes treated with Bro-injection (p = 0.35). The Bro-Naïve group improved better in PED measurement (mean difference: 297.92 ± 72,32) as compared to the Bro-Switch group (mean difference: 185.06 ± 11.07). On the contrary, no significant reduction in BCVA in the two groups was recorded (p = 0.66).

Conclusion: We suggest Bro-injection for w-AMD as effective anatomical outcomes in PED flattening, but not similar in visual results. Although this study evaluated short-term outcomes, the hopeful results can lead to interesting medium-long time effects.

查看原文本刊更多论文

布卢珠单抗对初治或无应答患者因渗出性黄斑变性引起的色素上皮脱落的疗效。

目的：研究渗出性年龄相关性黄斑变性（AMD）初治者或无反应者注射布卢珠单抗后的疗效：这是一项回顾性、比较性队列研究，自 2017 年 11 月至 2022 年 5 月，在巴里大学医院综合诊所三级转诊中心进行，为期 5 年。41只患有湿性AMD（湿性AMD）的眼睛接受了抗血管内皮生长因子（VEGF）的玻璃体内注射。样本分为两组：Bro-开关组和Bro-Naïve组。Bro-Switch组之前曾接受过其他抗血管内皮生长因子的静脉注射。Bro-Naïve组首先接受的治疗是Brolucizumab（Bro）。对注射 Bro 前后的色素上皮脱落（PED）和最佳矫正视力（BCVA）结果进行了评估：结果：所有接受Bro注射治疗的眼睛的PED测量值都明显下降（P = 0.35）。与 Bro 切换组（平均差：185.06 ± 11.07）相比，Bro-Naïve 组的 PED 测量改善更好（平均差：297.92 ± 72.32）。相反，两组的 BCVA 均无明显下降（P = 0.66）：结论：我们认为 Bro 注射治疗 w-AMD 在 PED 变平方面具有有效的解剖效果，但在视觉效果方面并不相似。虽然这项研究评估的是短期结果，但其令人充满希望的结果可能会带来有趣的中长期效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Ophthalmology 医学-眼科学

CiteScore

3.60

自引率

0.00%

发文量

372

审稿时长

3-8 weeks

期刊介绍： The European Journal of Ophthalmology was founded in 1991 and is issued in print bi-monthly. It publishes only peer-reviewed original research reporting clinical observations and laboratory investigations with clinical relevance focusing on new diagnostic and surgical techniques, instrument and therapy updates, results of clinical trials and research findings.